Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2020 - 2026)
Xilio Therapeutics (XLO) reported Depreciation & Amortization (CF) of $344000.0 for Q1 2026, down 30.78% on a YoY basis from $497000.0 in Q1 2025, and up 6.5% sequentially from $323000.0 in Q4 2025.
Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $344000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 30.78% year-over-year to $344000.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 18.26% YoY), and the FY2025 full-year result was $1.5 million, down 6.27% from the prior year.
- Depreciation & Amortization (CF) rose to $344000.0 in Q1 2026, from $323000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $499000.0 in Q1 2023 to a low of $323000.0 in Q4 2025.
- A 5-year average of $428000.0 and a median of $445000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) rose 25.71% in 2022 and plunged 30.78% in 2026, its largest moves.
- Tracing XLO's Depreciation & Amortization (CF) over 5 years: stood at $489000.0 in 2022, then declined by 8.18% to $449000.0 in 2023, then retreated by 16.26% to $376000.0 in 2024, then declined by 14.1% to $323000.0 in 2025, then advanced by 6.5% to $344000.0 in 2026.
- Business Quant data shows XLO's Depreciation & Amortization (CF) at $344000.0 in Q1 2026, $323000.0 in Q4 2025, and $340000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | 344,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 344,000.00 |
| Mar 31, 2026 | 344,000.00 |
| Dec 31, 2025 | 323,000.00 |
| Dec 31, 2025 | 323,000.00 |
| Sep 30, 2025 | 340,000.00 |
| Sep 30, 2025 | 340,000.00 |
| Jun 30, 2025 | 381,000.00 |
| Jun 30, 2025 | 381,000.00 |
| Mar 31, 2025 | 497,000.00 |
| Mar 31, 2025 | 497,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 380,000.00 |
| Sep 30, 2024 | 380,000.00 |
| Jun 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 445,000.00 |
| Mar 31, 2024 | 443,000.00 |
| Mar 31, 2024 | 443,000.00 |
| Dec 31, 2023 | 449,000.00 |
| Dec 31, 2023 | 449,000.00 |